[Dofetilide in patients with chronic heart failure and left ventricular dysfunction].
Latini
R
R
Istituto di Ricerche Farmacologiche M. Negri, Laboratorio di Farmacologia Clinica di Milano.
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000628:therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004554:Electric Countershock; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D010627:Phenethylamines / Q000627:therapeutic use*; D026902:Potassium Channel Blockers; D012307:Risk Factors; D013449:Sulfonamides / Q000627:therapeutic use*; D013997:Time Factors; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000401:mortality
D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D010627:Phenethylamines; D026902:Potassium Channel Blockers; D013449:Sulfonamides; C063533:dofetilide